ADVANCES IN TARGETED THERAPIES AND IMMUNOMODULATORY STRATEGIES IN LUPUS
Bibliographic record
Abstract
PV249 / #817 Poster Topic: AS24 - SLE-Treatment Background/Purpose Lupus is a complex autoimmune disease characterized by a dysregulated immune response and multiorgan involvement. Despite advances in conventional therapies, refractory diseases and treatment toxicity remain a challenge. This manuscript reviews the evolving landscape of biomedicines and immunomodulatory therapies, focusing on targeted approaches to address SLE pathogenesis. Methods To provide an overview of therapeutic potential of new immunomodulatory agents targeting key pathogenic pathways in SLE, emerging treatment strategies, using cytokine inhibition, B/T cell activation, co-stimulation blockade, kinase modulation, and cellular therapies, while addressing mechanistic insights from recent clinical trials. We have performed a comprehensive review and analysis of Systemic Lupus Erythematosus (SLE) clinical studies synopsis protocols, of randomized controlled trials (RCTs), and real-world data was conducted. Also, a review of published abstracts and publications of phase 1, 2 and 3 studies. Results Phase 3 Successes: Type I interferon receptor antagonists (eg, anifrolumab) and BAFF/BLyS inhibitors (eg, belimumab) have demonstrated robust efficacy in reducing disease activity and flares, for moderate-to-severe SLE. Voclosporin have demonstrated efficacy in lupus nephritis and JAK/STAT inhibitors such as upadacitinib show promise in lupus nephritis, with pivotal Phase 3 trials underway. Phase 2 Innovations: Anti-CD40L therapies (eg, dapirolizumab pegol) exhibit potential in SLE by targeting B/T cell interactions and glomerular inflammation. The depleting anti-BAFF-R antibody ianalumab has also shown excellent preliminary efficacy in phase 2 trial. Anti-BDCA2 antibodies (eg, litifilimab) and TYK2 inhibitors (eg, deucravacitinib) improve cutaneous and systemic manifestations. Phase 1 Explorations: Novel strategies include epigenetic modulators (eg, JNK inhibitors) to address DNA methylation, CAR-T cell therapies targeting B cell markers (eg, CD19) for refractory disease, and S1P receptor modulators to limit lymphocyte trafficking. Conclusions The SLE therapeutic landscape is undergoing rapid transformation, driven by precision targeting of cytokine signaling, co-stimulation pathways, and intracellular kinase networks. While Phase 3 successes underscore the viability of immunomodulation, Phase 1/2 innovations in epigenetic and cellular therapies offer transformative potential for refractory cases. Collaborative efforts to standardize endpoints, validate predictive biomarkers, and ensure equitable access are essential to optimize outcomes and translate these advances into global patient care.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.010 | 0.003 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".